Organovo Holdings Inc.

Company Snapshot

Founded: 2007
Entity Type: Public
Employees: 20
Region: U.S.
Revenue: $0.1 Millions
Revenue Year: 2023
Headquarter: U.S.
Key Geographics: U.S.
Corporate Address: 11555 Sorrento Valley Road, Suite 100 San Diego, California 92121 U.S. Tel: +1-(858)-224-1000 Web: www.organovo.com

Company Overview

Organovo is a clinical-stage biotechnology company dedicated to developing drugs proven effective in three-dimensional (3D) human tissues as potential candidates for drug development. The company utilizes proprietary technology to construct 3D human tissues replicating essential aspects of native human tissue composition, architecture, function, and disease characteristics. 

Financial Highlights (FY 2023)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Organovo Holdings Inc. In Reports

3D Cell Cultures: Technologies and Global Markets

BCC Research Market Analyst says global market for 3D cell culture is estimated to increase from $4.6 billion in 2023 to reach $14.8 billion by 2028 at a CAGR of 26.5% from 2023 through 2028.

Bioprinting: Technologies and Global Markets

Global bioprinting technologies market should reach $5.0 billion by 2027 from $2.4 billion in 2022 at a CAGR of 16.2% for the forecast period of 2022-27.

Advanced Materials for 3D Printing: Technologies and Global Markets

Global advanced materials for 3D printing market should reach $2.5 billion by 2022 and more than $6.5 billion by 2027, with a CAGR of 20.7% during the forecast period of 2022-27.

Company's Business Segments

  • Research & Development : This segment includes the company's drug development efforts.
  • Mosaic Cell Sciences : This segment serves as a key source of certain primary human cells, which are utilized in research and development efforts.

Applications/End User Industries

  • Biotechnology
  • Pharmaceuticals